Merck and Moderna said Wednesday that their personalized mRNA therapy, intismeran autogene, met its primary endpoints in a phase 3 melanoma trial [1].
This result marks a significant milestone in oncology, as it is the first positive phase 3 result for any mRNA-based cancer treatment [1]. The success suggests that the technology used in recent global vaccine efforts can be effectively adapted to treat specific malignancies.
The therapy is an individualized neoantigen vaccine designed to prevent melanoma from returning after initial treatment [1], [4]. By targeting specific mutations unique to a patient's tumor, the vaccine aims to prime the immune system to recognize and destroy remaining cancer cells.
According to trial data, the treatment significantly reduced the risk of the cancer returning [4] and curbed melanoma recurrence [5]. While specific percentage reductions were not detailed in the announcement, the meeting of primary endpoints indicates the therapy achieved its intended clinical effect [1].
The financial markets reacted sharply to the clinical news. Moderna's stock more than doubled following the announcement [3].
The partnership between Merck (also known as MSD) and Moderna focused on evaluating how a personalized approach to mRNA could outperform standard care in preventing recurrence [1], [4]. This phase 3 trial represents the final major hurdle before a company can seek regulatory approval for widespread clinical use.
“The first positive phase 3 result for an mRNA-based cancer treatment.”
The success of intismeran autogene validates the 'personalized medicine' approach, where treatments are tailored to the genetic sequence of an individual's tumor rather than using a one-size-fits-all drug. If regulatory approval follows, this could shift the standard of care for melanoma patients from passive monitoring to active immunotherapy to prevent relapse, potentially creating a blueprint for treating other solid tumors using mRNA technology.
